Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: CALGB 100801 Principal Investigator: Vij, Ravi
Title: Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
Phase: II Disease Site: Multiple Sites
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to find out what effects (good and bad) this treatment has on patients and their cancer. This study is adding the drug azacitidine to a transplant, to see if it improves the outcome of the transplant.

This research is being done to improve the outcome of patients diagnosed with myelodysplastic syndromes or acute myeloid leukemia who have achieved a complete remission with their initial therapy through the addition of azacitidine post-transplant.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)